YOUR FASTEST PATH TO NOVEL THERAPEUTICS
Partnering with
OUR BUSINESS DEVELOPMENT TEAM
At Distributed Bio, we pioneer new partnerships in drug discovery and provide a novel path to therapeutics. We generate free, fully human pico molar binders faster than you can immunize a mouse. By working closely alongside our R&D team, we deliver technologies that are constantly evolving with unprecedented speed and developability.
Visit our Work With Us section to explore how you can partner with us.
CURRENT PARTNERSHIPS
SUPERHUMAN PLATFORM LICENSE AGREEMENT
Distributed Bio has transferred and licensed its proprietary SuperHuman 2.0 antibody discovery platform to Pfizer, for the identification of novel antibodies for use as therapeutic targets. Specifically, Pfizer will use the library to perform screening activities against Pfizer-selected targets. Pfizer has also secured access to continued improvements to the SuperHuman 2.0. This is Distributed Bio Inc.’s ninth SuperHuman 2.0 platform transfer.
"The SuperHuman Platform represents the culmination of a decade of our research in computational library design"...see press release
PARTNERSHIP ON ANTIBODY THERAPEUTIC DESIGN PLATFORM
Distributed Bio will collaborate with Twist Biosciences to offer therapeutic antibody design and optimization services, as well as an exclusive Gprotein coupled Receptor (GPCR) targeting library, for Twist Bioscience customers. Distributed Bio will develop and supply to Twist Biosciences a custom software solution for optimized antibody design that will integrate into Twist Bioscience’s eCommerce platform.
“Distributed Bio is singularly qualified, through their depth and breadth of experience designing antibodies based on the natural human repertoire, to develop customized software for our customers”...see press release
SUPERHUMAN PLATFORM TRANSFER
Distributed Bio will transfer and license its proprietary SuperHuman 2.0 antibody discovery platform to Boehringer Ingelheim who has also secured access to continued improvements to the SuperHuman Platform. Boehringer Ingelheim will use the platform for accelerating biotherapeutics discovery across therapeutic areas.
"The result is a library of 76 billion antibodies that contains over 5,000 hits against any antigen, including hundreds of picomolar binders, all thermostable, non-immunogenic, pre-screened by human blood and therapeutically developed in advance to avoid engineering delays downstream"....see press release
MULTI-TARGET COLLABORATION
Distributed Bio will screen its proprietary SuperHuman antibody platform to discover therapeutic ready pre-optimized antibodies against multiple Pandion targets. Pandion will have the right to develop and commercialize therapeutic programs resulting from the collaboration. Pandion will also directly license multiple lead antibodies from Distributed Bio and may internalize the SuperHuman Platform.
"We’re delighted to be working with the most innovative company in antibody discovery,"...see press release
SUPERHUMAN PLATFORM TRANSFER
Kadmon will license the Distributed Bio SuperHuman platform for accelerating the discovery of antibody based drugs. Kadmon has also secured access to continued improvements to the SuperHuman Platform.
"This is an order of magnitude more molecules than can be generated by other technologies, and will enable our partners at Kadmon to search for ultra-high affinity, species-cross reactive and exquisitely specific therapeutic antibodies at unprecedented speeds and with the confidence that their molecules will be best in class every time."...see press release
